Skip to main navigation
Skip to search
Skip to main content
The Capital Region of Denmark's Research Portal Home
Dansk
English
Search content at The Capital Region of Denmark's Research Portal
Home
Hospitals/Departments
Researchers
Research output
Activities
Prizes
Specific CDK4/6 inhibition in breast cancer: a systematic review of current clinical evidence
Anne Polk
,
Ida Lykke Kolmos
,
Iben Kümler
, Dorte Lisbeth Nielsen
Department of Oncology
33
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Specific CDK4/6 inhibition in breast cancer: a systematic review of current clinical evidence'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Hormone Receptor
42%
Palbociclib
42%
Biological Marker
28%
Letrozole
28%
Fulvestrant
28%
Retinoblastoma Protein
28%
Malignant Neoplasm
14%
Adverse Event
14%
Endocrine Therapy
14%
Clinical Trial
14%
Infection
14%
Phase II Trials
14%
Progression Free Survival
14%
Neutropenia
14%
Gastrointestinal Toxicity
14%
Retinoblastoma
14%
Cyclin Dependent Kinase
14%
Ribociclib
14%
Abemaciclib
14%
Phase III Trials
14%
Keyphrases
CDK4/6 Inhibition
100%
Hormone receptor-positive/HER2-negative Breast Cancer
60%